PBT: Further vindication of PBT's strategy with their compound PBT2 targeting Alzheimer's disease comes from this morning's CGS announcement. See PBT post below. It could be a good day for both stocks.
CGS has a very interesting announcement out this morning about a new test for the early detection of Alzheimer's disease.
They have found that people with elevated levels of beta amyloid can be used as a marker for very early stages of the disease.
What they have found is that people who do not display any symptoms of Alzheimers but have high beta amyloid in the brain, over time, showed a subtle but progressive decline in their memory.
This sounds like further evidence supporting PBT's research with their candidate PBT2, which works by preventing the accumulation of the beta amyloid protein in the brain.
This story continues to become more compelling over time.
